Skip to main content
SpringerLink
Log in

Acute effect of an alpha1-adrenoceptor antagonist on urinary sodium excretion, plasma atrial natriuretic peptide, arginine vasopressin, and the renin-aldosterone system in healthy subjects

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

To elucidate the mechanism underlying the sodium retention caused byα 1-adrenoceptor blockade in man, a placebo-controlled, randomised, double-blind study has been made of the acute effects of bunazosin anα 1-antagonist, on urinary sodium excretion, atrial natriuretic peptide (ANP), arginine vasopressin (AVP), and the renin-aldosterone system in 7 healthy men.

A single oral dose of bunazosin 2.0 mg caused a significant reduction (P < 0.05) in urinary sodium excretion after 0–2 h, 2–4 h, and 4–6 h. The mean values for plasma ANP, AVP, aldosterone, and cortisol concentrations at those times were similar after placebo and bunazosin, and plasma renin activity was significantly increased 2 and 4 h after bunazosin.

Pretreatment with oral enalapril 10 mg, an angiotensin converting enzyme inhibitor, did not prevent the bunazosin-induced reduction in urinary sodium excretion.

There was a significant positive correlation between the drug-induced changes in blood pressure and urinary sodium excretion.

The results suggest that ANP, AVP, and renin-aldosterone may play little role in the sodium retention caused by acuteα 1-adrenoceptor blockade in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Slick GL, Auilera AF, Zambraski EJ, DiBona GF, Kaioyanides GL (1975) Renal neuroadrenergic transmission. Am J Physiol 229: 1760–1765

    Google Scholar 

  2. Zambraski EJ, DiBona GF, Galoyanides GL (1975) Specificity of neural effect on renal tubular sodium reabsorption. Proc Soc Exp Biol Med 151: 543–546

    Google Scholar 

  3. DiBona GF, Sawin LL (1983) Renal nerves in renal adaptation to dietary sodium restriction. Am J Physiol 245: 17322–17323

    Google Scholar 

  4. Rogenes PR, Gottschalk CW (1982) Renal function in conscious rats with chronic unilateral renal denervation. Am J Physiol 242: F140-F148

    Google Scholar 

  5. Osborn JL, Holdaas H, Thames MD, DiBona GF (1983) Renal adrenoceptor mediation of antinatriuretic and renin secretion response to low frequency renal nerve stimulation in the dog. Circ Res 53: 298–305

    Google Scholar 

  6. Hesse IFA, Johns EJ (1984) The subtype of alpha-adrenoceptor involved in the neural control of renal tubular sodium reabsorption in the rabbit. J Physiol (Lond) 352: 527–538

    Google Scholar 

  7. Stanaszek WF, Kellerman D, Brogden EN, Romankiewicz JA (1983) Prazosin up-date: a review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25: 339–384

    Google Scholar 

  8. Koshy MC, Mickley D, Bourgoignie J, Blaufox MD (1977) Physiologic evaluation of a new antihypertensive agent: prazosin HCl. Circulation 55: 533–537

    Google Scholar 

  9. Smyth DD, Umemura S, Pettinger WA (1986) Renal α2-adrenergic receptors multiply and mediate sodium retention after prazosin treatment. Hypertension 8: 323–331

    Google Scholar 

  10. Kaplan NM (1990) Clinical hypertension. 5th ed. Williams and Wilkins, Baltimore, p 211

    Google Scholar 

  11. DiBona GF (1985) Neural regulation of renal tubular sodium reabsorption and renin secretion. Fed Proc 44:2816–2822

    Google Scholar 

  12. De Leeuw PW, Van ES PN, De Bos R, Birkenhager WH (1987) Role of α2-adrenergic receptors in the human hypertensive kidney. Hypertension 9 [Suppl 111]: III210-III212

    Google Scholar 

  13. Sonnenberg H, Veress AT (1984) Cellular mechanisms of release of atrial natriuretic factor. Biochem Biophys Res Commun 124: 443–449

    Google Scholar 

  14. Currie MG, Newman WH (1986) Evidence for α1-adrenergic receptor regulation of atriopeptin release from the isolated rat heart. Biochem Biophys Res Commun 137: 94–100

    Google Scholar 

  15. Kimura T, Shoji M, Iitake K, Ota K, Matsui K, Yoshinaga K (1984) The role of central α1 and α2-adrenoceptors in the cardiovascular system. Endocrinology 114: 1426–1432

    Google Scholar 

  16. Inenaga K, Dyball RE, Okuya S, Yamashita H (1986) Characterization of hypothalamic noradrenalin receptors in the supraoptic nucleus and periventricular region of the paraventricular nucleus of mice in vitro. Brain Res 369: 37–47

    Google Scholar 

  17. Shoji T, Daiku Y, Igarashi T (1980) Alpha-adrenoceptor blocking properties of a new antihypertensive agent, 2-[4-(n-butyryl)homopiperazine-1-yl]-4-amino-6,7-dimethoxy-quinazolin (E643). Jap J Pharmacol 30: 763–772

    Google Scholar 

  18. Hata F, Kondo E, Kondo S, Kagawa K (1981) Characteristics of (3H) E-643-binding to alpha adrenoceptors. Jap J Pharmacol 32: 181–187

    Google Scholar 

  19. Ishizaki T, Baba T, Murabayashi S, Kubota K, Hara K, Kurimoto F (1988) Effects of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers. J Cardiovasc Pharmacol 12: 512–519

    Google Scholar 

  20. Baba T, Murabayashi S, Tomiyama T, Takebe K (1990) The pharmacokinetics of enalapril in patients with compensated liver cirrhosis. Br J Clin Pharmacol 29: 766–769

    Google Scholar 

  21. Haber E, Koerner T, Page LB, Klinman B, Purnode A (1969) Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 29: 1349–1355

    Google Scholar 

  22. Ogihara T, Iinuma K, Nishi K, Arakawa Y, Takagi A, Kurata K, Miyai K, Kumahara Y (1977) A non-chromatographic non-extraction radioimmunoassay for serum aldosterone. J Clin Endocrinol Metab 45: 726–731

    Google Scholar 

  23. Naruse M, Naruse K, Obana K, Kurimoto F, Sakurai H, Honda T, Higashida T, Demura H, Inagami T, Shizume K (1986) Immunoreactiveα-human atrial natriuretic polypeptide in human plasma. Peptides 7:141–145

    Google Scholar 

  24. Sakurai H, Kanai A, Nomura K, Demura H, Shizume K (1986) A simple and highly sensitive radioimmunoassay for 8-arginine vasopressin in human plasma using a reversed-phase C18 silica column. J Tokyo Women's Med Coll 56: 34–38

    Google Scholar 

  25. Donckier J, Anderson JV, Yeo T, Bloom SR (1986) Diurnal rhythm in the plasma concentration of atrial natriuretic peptide. New Engl J Med 315: 710

    Google Scholar 

  26. Rubin P, Jackson G, Blaschke T (1980) Studies on the clinical pharmacology of prazosin. II: The influence of indomethacin and of propranolol on the action and disposition of prazosin. Br J Clin Pharmacol 10: 33–39

    Google Scholar 

  27. McAreavey D, Cumming AM, Sood VP, Leckie BJ, Morton JJ, Murray GD, Robertson JI (1981) The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in men. Clin Sci 61: 457s-460s

    Google Scholar 

  28. Hall JE, Guyton AC (1990) Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In: Laragh JH, Brenner BM (eds) Hypertension: pathopysiology, diagnosis, and management. Raven Press, New York, pp 1105–1129

    Google Scholar 

  29. Johnson MD, Malvin RL (1986) Stimulation of renal sodium reabsorption by angiotensin II. Am J Physiol 232: F298-F306

    Google Scholar 

  30. Faubert PF, Chou SY, Porush JG (1987) Regulation of papillary plasma flow by angiotensin II. Kidney Int 32: 472–478

    Google Scholar 

  31. Jeffries WB, Tam L-T, Wang Y, Smyth DD, Pettinge WA (1987) Prazosin-induced alterations in renal a-adrenergic receptor function. Hypertension 9 [Suppl. III): III125-III129

    Google Scholar 

  32. Awan NA, Lee G, DeMaria AN, Mason DT (1981) Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. Am Heart J 101: 541–547

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Third Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki

    T. Tomiyama & T. Baba

  2. Division of Clinical Pharmacology, Clinical Research Institute, National Medical Center, Tokyo

    T. Baba & T. Ishizaki

  3. First Department of Internal Medicine, Aomori Municipal Hospital, Aomori, Japan

    S. Murabayashi

  4. Division of Clinical Pharmacology, Clinical Research Institute National Medical Center, 1-21-2 Toyama, Shinjuku-ku, 162, Tokyo, Japan

    T. Baba

Authors
  1. T. Tomiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Murabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Ishizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomiyama, T., Baba, T., Murabayashi, S. et al. Acute effect of an alpha1-adrenoceptor antagonist on urinary sodium excretion, plasma atrial natriuretic peptide, arginine vasopressin, and the renin-aldosterone system in healthy subjects. Eur J Clin Pharmacol 43, 17–21 (1992). https://doi.org/10.1007/BF02280748

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02280748

Key words

Search

Navigation